| Menaquinone-7 as a novel pharmacological therapy in the treatment of rheumatoid arthritis: A clinical study 2015 · MK-7 treated group · Adults with rheumatoid arthritis; 24 male and 60 female across the study, average age 47.2 years | 100 mcg | 90 days | 42 |
| Comparison of concurrent treatment with vitamin K(2) and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03 2017 · risedronate and vitamin K2 group · Women aged 65 years or older with osteoporosis | 45 mg | 2 years | 931 |
| Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis 2000 · vitamin K2-treated group · Patients with osteoporosis; age and sex not reported | 45 mg | 2 years | 120 |
| Effect of menatetrenone, a vitamin k2 analog, on recurrence of hepatocellular carcinoma after surgical resection: a prospective randomized controlled trial 2012 · MNT group · Patients undergoing curative hepatectomy for primary hepatocellular carcinoma | 45 mg | — | 50 |
| Anticancer effects of vitamin K combined with transarterial chemoembolization in hepatocellular carcinoma, a randomized controlled trial 2025 · TACE + vitamin K group · Adults aged 18–89 with unresectable hepatocellular carcinoma | 45 mg | 4 weeks | 50 |
| The effect of menatetrenone, a vitamin K2 analog, on disease recurrence and survival in patients with hepatocellular carcinoma after curative treatment: a pilot study 2006 · menatetrenone group · Patients diagnosed as free of hepatocellular carcinoma after surgical resection or percutaneous local ablation | 45 mg | 3 years | 32 |
| Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection 2007 · vitamin K2 group · Patients with hepatitis C virus infection and hepatocellular carcinoma, free of disease after radiofrequency ablation or surgery | 45 mg | — | 30 |
| Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: A phase II, randomized study 2021 · Sorafenib + vitamin K · Adults aged 18–85 with advanced hepatocellular carcinoma | 45 mg | — | 22 |
| Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma 2009 · VK single treatment · Patients after curative therapy for hepatocellular carcinoma; age and sex not reported | 45 mg | 1461 days | — |
| Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma 2009 · Combination treatment with VK and ACE-I · Patients after curative therapy for hepatocellular carcinoma; age and sex not reported | 45 mg | 1461 days | — |
| The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial 2011 · menatetrenone group · elderly patients with Alzheimer disease and hypovitaminosis K and D | 45 mg | 1 year | — |
| Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. A double-blind randomised clinical trial 2015 · MK-7 · Healthy postmenopausal women | 180 mcg | 3 years | 120 |
| Vitamin K2 in Managing Nocturnal Leg Cramps: A Randomized Clinical Trial 2024 · vitamin K2 · Adults aged 65 years and older with at least 2 documented nocturnal leg cramp episodes during the 2-week screening period | 180 mcg | 8 weeks | 103 |
| Effect of vitamin K2 administration on depression status in patients with polycystic ovary syndrome: a randomized clinical trial 2022 · intervention group (vitamin-administered arm) · Women aged 18–40 with polycystic ovary syndrome | 90 mcg | 8 weeks | 42 |
| Vitamin K-induced effects on body fat and weight: results from a 3-year vitamin K2 intervention study 2018 · vitamin K2 (MK-7) group · Postmenopausal women aged 55–65 years | 180 mcg | 3 years | — |
| Association of vitamin K status with adiponectin and body composition in healthy subjects: uncarboxylated osteocalcin is not associated with fat mass and body weight 2012 · menaquinone-4 group · Postmenopausal women | 45 mg | 3 years | 164 |
| Effect of Menaquinone-7 Supplementation on Arterial Stiffness in Chronic Hemodialysis Patients: A Multicenter Randomized Controlled Trial 2023 · Treatment group (oral MK-7) · Adults aged 18 years or older receiving maintenance hemodialysis, with carotid-femoral pulse wave velocity (cfPWV) of at least 10 m/s | 375 mcg | 24 weeks | 50 |
| Vitamin K2 as a potential therapeutic candidate for the prevention of muscle cramps in hemodialysis patients: A prospective multicenter, randomized, controlled, crossover pilot trial 2022 · Vitamin K2 · Adults with maintenance hemodialysis and muscle cramps refractory to conventional interventions; age and sex not reported | 360 mcg | 4 weeks | 39 |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · vitamin K1 · Healthy, nonosteoporotic Scottish women aged 60 years or older | 200 mcg | 2 years | — |
| Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women 2013 · MK-7 · Healthy postmenopausal women; age not reported | 180 mcg | 3 years | — |
| Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study 2020 · 50 µg/day group · Community-dwelling men and postmenopausal women aged 50–75 years | 50 mcg | 1 year | — |
| Effect of Low-Dose Vitamin K2 Supplementation on Bone Mineral Density in Middle-Aged and Elderly Chinese: A Randomized Controlled Study 2020 · 90 µg/day group · Community-dwelling men and postmenopausal women aged 50–75 years | 90 mcg | 1 year | — |
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 64 mcg | — | — |
| Vitamins K2 and D3 Improve Long COVID, Fungal Translocation, and Inflammation: Randomized Controlled Trial 2025 · vitamin K2/D3 arm · Adults aged 18 years or older with at least two moderate-intensity long COVID symptoms persisting for at least three months after COVID-19 infection | 240 mcg | 24 weeks | 98 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Jarlsberg group — female participants · Female cross-country and biathlon skiers aged 17–27 | 64 mcg | 24 weeks | 15 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Norvegia group — male participants · Male cross-country and biathlon skiers aged 18–25 | 40 mcg | 24 weeks | 15 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Jarlsberg group — male participants · Male cross-country and biathlon skiers aged 18–30 | 77 mcg | 24 weeks | 14 |
| Comparison of cheese with and without Propionibacterium freudenreichii subsp. shermanii LMGT 2951 on off-season muscle strength and VO(2) max development in Nordic skiers: a randomized clinical trial 2025 · Norvegia group — female participants · Female cross-country and biathlon skiers aged 17–26 | 33 mcg | 24 weeks | 14 |
| Reducing Undercarboxylated Osteocalcin With Vitamin K Supplementation Does Not Promote Lean Tissue Loss or Fat Gain Over 3 Years in Older Women and Men: A Randomized Controlled Trial 2017 · Vitamin K group · Community-dwelling men and women aged 60–80 years | 500 mcg | 3 years | — |
| Amelioration of osteoporosis by menatetrenone in elderly female Parkinson's disease patients with vitamin D deficiency 2002 · treated group · elderly female patients with Parkinson's disease and vitamin D and K deficiencies | 45 mg | 1 year | 60 |
| Menatetrenone ameliorates osteopenia in disuse-affected limbs of vitamin D- and K-deficient stroke patients 1998 · MK-4 group · Hemiplegic patients following stroke with vitamin D and K deficiencies | 45 mg | 1 year | 54 |
| The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial 2023 · vitamin K1 arm · Post-menopausal women aged 55–85 with osteoporosis and low screening serum vitamin K1, receiving established oral bisphosphonate treatment | 1 mg | 548 days | 35 |
| The additive effect of vitamin K supplementation and bisphosphonate on fracture risk in post-menopausal osteoporosis: a randomised placebo controlled trial 2023 · MK-4 arm · Post-menopausal women aged 55–85 with osteoporosis and low screening serum vitamin K1, receiving established oral bisphosphonate treatment | 45 mg | 548 days | 35 |
| Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate 2001 · M group · Postmenopausal women aged 53–78 with osteoporosis, more than 5 years after menopause | 45 mg | 2 years | 23 |
| Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis 2000 · K group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause | 45 mg | 2 years | 22 |
| Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women 2008 · vitamin K(2) plus alendronate (group AK) · postmenopausal women with osteoporosis | 45 mg | 1 year | 22 |
| Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine 2004 · vitamin K2 alone (group K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported | 45 mg | 8 weeks | 15 |
| Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis 2000 · Group 2 · Patients with chronic glomerulonephritis scheduled for prednisolone treatment; age and sex not reported | 45 mg | 10 weeks | 10 |
| Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG) 2005 · group B · Patients with chronic glomerulonephritis starting glucocorticoid treatment; age and sex not reported | 15 mg | 1 year | 10 |
| Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial 2010 · MK-7 group · Healthy postmenopausal women aged 50–60 years, 1–5 years after menopause | 360 mcg | 1 year | — |
| Effect of Vitamin K on Vascular Health and Physical Function in Older People with Vascular Disease--A Randomised Controlled Trial 2016 · Vitamin K · Community-dwelling adults aged 70 and over with hypertension, diabetes mellitus, or previously diagnosed vascular disease; men and women | 100 mcg | 26 weeks | 40 |
| Daily vitamin K supplementation improves anticoagulant stability 2007 · vitamin K group · Patients using phenprocoumon, a vitamin K antagonist | 100 mcg | 24 weeks | — |
| Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study 2011 · 100 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation | 100 mcg | 1 year | — |
| Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials 2015 · 100 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years | 100 mcg | 4 weeks | — |
| Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials 2015 · MK-7 group (Study 2) · Subjects aged 20–69 years; sex and health condition not specified | 100 mcg | 12 weeks | — |
| Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial 2008 · vitamin K group · Postmenopausal women with osteopenia; mean age 59 years, range 40–82 | 5 mg | 4 years | 217 |
| Menatetrenone versus alfacalcidol in the treatment of Chinese postmenopausal women with osteoporosis: a multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial 2014 · Group M (menatetrenone) · Women aged 45–75 years, postmenopausal for at least 5 years, with osteoporosis | 45 mg | 1 year | 118 |
| Vitamin K supplement along with vitamin D and calcium reduced serum concentration of undercarboxylated osteocalcin while increasing bone mineral density in Korean postmenopausal women over sixty-years-old 2011 · treatment group (vitamin K) · Postmenopausal Korean women over 60 years old | 45 mg | 26 weeks | 40 |
| Vitamin K2 treatment for postmenopausal osteoporosis in Indonesia 2006 · vitamin K2 group · Postmenopausal women with osteoporosis | 45 mg | 48 weeks | 33 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK1 group · Postmenopausal women | 100 mcg | 1 year | 26 |
| Possible site-specific effect of an intervention combining nutrition and lifestyle counselling with consumption of fortified dairy products on bone mass: the Postmenopausal Health Study II 2011 · CaDK2 group · Postmenopausal women | 100 mcg | 1 year | 24 |
| Effect of combined administration of vitamin D3 and vitamin K2 on bone mineral density of the lumbar spine in postmenopausal women with osteoporosis 2000 · DK group · Postmenopausal women aged 55–81 years with osteoporosis, more than 5 years after menopause | 45 mg | 2 years | 21 |
| Protective effect of vitamins K2 and D3 on prednisolone-induced loss of bone mineral density in the lumbar spine 2004 · vitamins D3 plus K2 (group D + K) · Patients with chronic glomerulonephritis receiving prednisolone; age and sex distribution for this arm not reported | 45 mg | 8 weeks | 15 |
| Two-year randomized controlled trial of vitamin K1 (phylloquinone) and vitamin D3 plus calcium on the bone health of older women 2007 · combined vitamins K1 and D3 plus calcium · Healthy, nonosteoporotic Scottish women aged 60 years or older | 200 mcg | 2 years | — |
| The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial 2021 · vitamin K2 (MK-7) group · Postmenopausal women with osteopenia | 375 mcg | 1096 days | — |
| The effect of menaquinone-7 supplementation on dp-ucMGP, PIVKAII, inflammatory markers, and body composition in type 2 diabetes patients: a randomized clinical trial 2022 · MK-7 group · Adults aged 20–55 years with type 2 diabetes and BMI 27–35 kg/m²; men and women | 200 mcg | 12 weeks | 23 |
| Vitamin K in breast milk: no influence of maternal dietary intake 1993 · supplemented group · Lactating mothers, 4 to 91 days postpartum | 88 mcg | 13 weeks | 20 |
| Excretion of the urinary 5C- and 7C-aglycone metabolites of vitamin K by young adults responds to changes in dietary phylloquinone and dihydrophylloquinone intakes 2007 · phylloquinone repletion diet · adults; age and health condition not specified | 206 mcg | 10 days | 9 |
| Excretion of the urinary 5C- and 7C-aglycone metabolites of vitamin K by young adults responds to changes in dietary phylloquinone and dihydrophylloquinone intakes 2007 · dihydrophylloquinone repletion diet · adults; age and health condition not specified | 240 mcg | 10 days | 9 |
| Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women 2012 · MK-4 group, Study 2 · Healthy women aged 20–21 years | 60 mcg | 7 days | 5 |
| Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women 2012 · MK-7 group, Study 2 · Healthy women aged 20–21 years | 60 mcg | 7 days | 5 |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 90 μg/day · Healthy Dutch men and women aged 18–45 years | 90 mcg | — | — |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 180 μg/day · Healthy Dutch men and women aged 18–45 years | 180 mcg | — | — |
| The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein 2012 · 180 μg/d MK-7 supplementation group · Adults aged 40–65 years; sex and health condition not specified | 180 mcg | 12 weeks | — |
| Effect of a combination of genistein, polyunsaturated fatty acids and vitamins D3 and K1 on bone mineral density in postmenopausal women: a randomized, placebo-controlled, double-blind pilot study 2013 · geniVida bone blend (GBB) · Healthy postmenopausal women aged 45–55 years, 1–3 years since their last spontaneous menstrual bleeding | 150 mcg | 26 weeks | 31 |
| Vitamin K1 supplementation retards bone loss in postmenopausal women between 50 and 60 years of age 2003 · MDK group · Healthy postmenopausal women aged 50–60 years | 1 mg | 3 years | — |
| Effects of One-Year Menaquinone-7 Supplementation on Vascular Stiffness and Blood Pressure in Post-Menopausal Women 2025 · MK-7 · Post-menopausal women aged 40–70 with low extrahepatic vitamin K status (dp-ucMGP >400 pmol/L) | 180 mcg | 1 year | 48 |
| Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin 2007 · Vitamin K supplementation · Warfarin-treated patients with previously unstable anticoagulation control | 150 mcg | 26 weeks | 35 |
| Effect of 200μG/day of vitamin K1 on the variability of anticoagulation control in patients on warfarin: a randomized controlled trial 2013 · intervention · Adults with unstable anticoagulation control while receiving warfarin; most had venous thromboembolism | 200 mcg | 26 weeks | 26 |
| The effect of vitamin K2 supplementation on vascular calcification in haemodialysis patients: a 1-year follow-up randomized trial 2019 · vitamin K2 group · Patients on haemodialysis | 200 mcg | 1 year | 22 |
| Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin 2000 · vitamin K(1) · Postmenopausal women about 60 years old with normal or low bone mineral density | 80 mcg | 1 year | — |
| Effects of a hydrogenated form of vitamin K on bone formation and resorption 2001 · phylloquinone repletion · 15 young adults | 200 mcg | 10 days | — |
| Effects of a hydrogenated form of vitamin K on bone formation and resorption 2001 · dihydrophylloquinone repletion · 15 young adults | 200 mcg | 10 days | — |
| Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study 2011 · 150 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation | 150 mcg | 1 year | — |
| Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study 2011 · 200 μg vitamin K(1) group · Adults starting vitamin K antagonists, regardless of history of unstable anticoagulation | 200 mcg | 1 year | — |
| Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial 2012 · 135 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis | 135 mcg | 6 weeks | — |
| Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials 2015 · 50 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years | 50 mcg | 4 weeks | — |
| Low-Dose Daily Intake of Vitamin K(2) (Menaquinone-7) Improves Osteocalcin γ-Carboxylation: A Double-Blind, Randomized Controlled Trials 2015 · 200 μg menaquinone-7 group (Study 1) · Postmenopausal women aged 50–69 years | 200 mcg | 4 weeks | — |
| No Detectable Coagulation Activation After Vitamin K (MK-7) Supplementation in Patients on Dialysis With Functional Vitamin K Deficiency: A One-Year Randomized, Placebo-Controlled Study 2024 · vitamin K (MK-7) · Patients on dialysis with functional vitamin K deficiency; age and sex not reported | 360 mcg | 52 weeks | 61 |
| The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children 2009 · MK-7-supplemented group · Healthy prepubertal children; sex and age range not specified | 45 mcg | 8 weeks | 28 |
| Effect of oral water soluble vitamin K on PIVKA-II levels in newborns 1995 · oral group · Full-term, healthy, breastfed newborns | 2 mg | 1 day | 24 |
| Effect of vitamin K1 supplementation on vitamin K status in cystic fibrosis patients 1997 · vitamin K1 supplementation · Outpatients with cystic fibrosis | 714 mcg | 4 weeks | 18 |
| Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women 2006 · vitamin K2 alone · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2 | 45 mg | 2 years | 17 |
| Plasma vitamin K1 and PIVKA-II after oral administration of mixed-micellar or cremophor EL-solubilized preparations of vitamin K1 to normal breast-fed newborns 1997 · Conventional Cremophor EL-solubilized preparation of vitamin K1 (Konakion drops) · Normal, fully breast-fed newborns | 2 mg | 1 day | 16 |
| Pharmacokinetics and efficacy of oral versus intravenous mixed-micellar phylloquinone (vitamin K1) in severe acute liver disease 2005 · oral K1 · Adults with severe acute liver disease | 10 mg | 1 day | 15 |
| Plasma vitamin K1 and PIVKA-II after oral administration of mixed-micellar or cremophor EL-solubilized preparations of vitamin K1 to normal breast-fed newborns 1997 · New mixed-micellar preparation of vitamin K1 (Konakion MM) · Normal, fully breast-fed newborns | 2 mg | 1 day | 14 |
| The effect of different meals on the absorption of stable isotope-labelled phylloquinone 2009 · Stable isotope-labelled phylloquinone capsule, given with each of the three test meals · Healthy adults aged 22–49 years, 5 women and 7 men | 20 mcg | 1 day | 12 |
| The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K(2,) in healthy subjects 2023 · Study II, single-dose MK-7 group · healthy male subjects; age not reported | 1 mg | 1 day | 12 |
| Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements 1997 · Stage II: mothers receiving 5 mg/d phylloquinone · Lactating mothers of human milk-fed infants; ages and health condition not specified | 5 mg | 12 weeks | 11 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 1000 μg phylloquinone group (dose-ranging RCT) · Adults with Crohn's disease, currently in remission | 1 mg | 2 weeks | 10 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 2000 μg phylloquinone group (dose-ranging RCT) · Adults with Crohn's disease, currently in remission | 2 mg | 2 weeks | 10 |
| Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements 1997 · Stage I: mothers receiving 2.5 mg/d phylloquinone · Lactating mothers; ages and health condition not specified | 2.5 mg | 6 weeks | 10 |
| Improving the vitamin K status of breastfeeding infants with maternal vitamin K supplements 1997 · Stage I: mothers receiving 5.0 mg/d phylloquinone · Lactating mothers; ages and health condition not specified | 5 mg | 6 weeks | 10 |
| Menaquinone-4 in breast milk is derived from dietary phylloquinone 2002 · 0.8 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant | 800 mcg | 12 days | 8 |
| Menaquinone-4 in breast milk is derived from dietary phylloquinone 2002 · 2.0 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant | 2 mg | 12 days | 8 |
| Menaquinone-4 in breast milk is derived from dietary phylloquinone 2002 · 4.0 mg/d phylloquinone group · Lactating mothers with a full-term healthy infant | 4 mg | 12 days | 7 |
| Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women 2012 · MK-4 group, Study 1 · Healthy women aged 20–21 years | 420 mcg | 1 day | 5 |
| Comparison of menaquinone-4 and menaquinone-7 bioavailability in healthy women 2012 · MK-7 group, Study 1 · Healthy women aged 20–21 years | 420 mcg | 1 day | 5 |
| The study of bioavailability and endogenous circadian rhythm of menaquinone-7, a form of vitamin K(2,) in healthy subjects 2023 · Study I, single-dose MK-7 group · healthy male subjects; age not reported | 1 mg | 1 day | 5 |
| Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults 1999 · broccoli diet · younger and older adult men and women | 377 mcg | 5 days | — |
| Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults 1999 · oil diet · younger and older adult men and women | 417 mcg | 5 days | — |
| Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding 2003 · oral group · Infants younger than 6 months with conjugated hyperbilirubinaemia | 2 mg | 1 day | — |
| Effects of oral and intramuscular vitamin K prophylaxis on vitamin K1, PIVKA-II, and clotting factors in breast fed infants 1992 · Oral vitamin K1 group · Healthy breast-fed infants given prophylaxis at birth | 1 mg | 1 day | — |
| Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis 2008 · 1 mg/day vitamin K1 · Children aged 8–18 years with pancreatic-insufficient cystic fibrosis | 1 mg | 30 days | — |
| Efficacy of high dose phylloquinone in correcting vitamin K deficiency in cystic fibrosis 2008 · 5 mg/day vitamin K1 · Children aged 8–18 years with pancreatic-insufficient cystic fibrosis | 5 mg | 30 days | — |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 10 μg/day · Healthy Dutch men and women aged 18–45 years | 10 mcg | — | — |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 20 μg/day · Healthy Dutch men and women aged 18–45 years | 20 mcg | — | — |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 45 μg/day · Healthy Dutch men and women aged 18–45 years | 45 mcg | — | — |
| Low-dose menaquinone-7 supplementation improved extra-hepatic vitamin K status, but had no effect on thrombin generation in healthy subjects 2012 · MK-7 360 μg/day · Healthy Dutch men and women aged 18–45 years | 360 mcg | — | — |
| The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein 2012 · 360 μg/d MK-7 supplementation group · Adults aged 40–65 years; sex and health condition not specified | 360 mcg | 12 weeks | — |
| Vitamin K2 supplementation improves hip bone geometry and bone strength indices in postmenopausal women 2007 · MK-4 group · Postmenopausal women aged 55–75 years, apparently healthy and non-osteoporotic | 45 mg | 3 years | 161 |
| Short-term menatetrenone therapy increases gamma-carboxylation of osteocalcin with a moderate increase of bone turnover in postmenopausal osteoporosis: a randomized prospective study 2009 · menatetrenone group · Postmenopausal patients with osteoporosis | 45 mg | 26 weeks | 56 |
| The effect of vitamin K4 supplementation on insulin resistance in individuals with type 2 diabetes: a double-blind randomised placebo-controlled clinical trial 2023 · Vitamin K group · Adults aged 18–65 with type 2 diabetes | 1 mg | 24 weeks | 45 |
| Six weeks phylloquinone supplementation produces undesirable effects on blood lipids with no changes in inflammatory and fibrinolytic markers in postmenopausal women 2008 · phylloquinone · postmenopausal women | 500 mcg | 6 weeks | 31 |
| Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial 2002 · Oral vitamin K · Patients with warfarin-associated coagulopathy and INR 4.5–10.0 | 1 mg | 1 day | 26 |
| Low-dose vitamin K2 (MK-4) supplementation for 12 months improves bone metabolism and prevents forearm bone loss in postmenopausal Japanese women 2014 · 1.5-mg MK-4 group · Postmenopausal Japanese women aged 50–65 years | 1.5 mg | 1 year | 24 |
| Dietary phylloquinone depletion and repletion in postmenopausal women: effects on bone and mineral metabolism 2006 · Phylloquinone repletion · Postmenopausal women, mean age 70 years | 450 mcg | 12 weeks | 21 |
| Effect of phylloquinone supplementation on glucose homeostasis in humans 2010 · experimental group · Community-dwelling postmenopausal women | 1 mg | 1 year | 21 |
| Effect of low dose vitamin K2 (MK-4) supplementation on bio-indices in postmenopausal Japanese women 2009 · MK-4 group · Healthy postmenopausal Japanese women aged 53–65 years | 1.5 mg | 4 weeks | 20 |
| Effect of vitamin K supplementation on serum calcification propensity and arterial stiffness in vitamin K-deficient kidney transplant recipients: A double-blind, randomized, placebo-controlled clinical trial 2023 · vitamin K2 · Vitamin K-deficient kidney transplant recipients | 360 mcg | 12 weeks | 20 |
| Effect of dietary fat content on oral bioavailability of menatetrenone in humans 1996 · Menatetrenone after meals with varied fat content · Healthy male volunteers; age not reported | 15 mg | 1 day | 18 |
| Phytomenadione or menadiol in the management of an elevated international normalized ratio (prothrombin time) 2000 · oral menadiol · Patients with cholestasis and an international normalized ratio greater than 1.2 | 20 mg | 3 days | 12 |
| Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation 1993 · group B · Patients with INR >5 and no bleeding complications; age and sex not reported | 2 mg | 1 day | 11 |
| The effect of dietary vitamin K on warfarin-induced anticoagulation 1991 · habitual diet supplemented with phytomenadione · Patients on stable anticoagulant treatment | 1 mg | — | 5 |
| Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation 2000 · phytonadione · Nonbleeding patients with excessive anticoagulation and INR 6.0–10.0 | 2.5 mg | 1 day | — |
| Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults 2000 · phylloquinone · Healthy adults aged 18–30 years and 65 years or older, approximately equally distributed by sex | 1 mg | 2 weeks | — |
| Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe 2001 · warfarin plus vitamin K · healthy adults who were CYP2C9*1 homozygotes | 10 mg | 1 day | — |
| A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation 2002 · Substudy B: 250-micro-g phylloquinone group · Healthy women and men aged 19–36 years | 250 mcg | 2 weeks | — |
| A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation 2002 · Substudy B: 375-micro-g phylloquinone group · Healthy women and men aged 19–36 years | 375 mcg | 2 weeks | — |
| A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation 2002 · Substudy B: 500-micro-g phylloquinone group · Healthy women and men aged 19–36 years | 500 mcg | 2 weeks | — |
| A high phylloquinone intake is required to achieve maximal osteocalcin gamma-carboxylation 2002 · Substudy B: 1000-micro-g phylloquinone group · Healthy women and men aged 19–36 years | 1 mg | 2 weeks | — |
| Vitamin K₂ alters bone metabolism markers in hemodialysis patients with a low serum parathyroid hormone level 2011 · vitamin K₂ group · Hemodialysis patients with low intact PTH levels (<100 pg/ml) | 45 mg | 1 year | — |
| Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial 2012 · 45 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis | 45 mcg | 6 weeks | — |
| Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial 2012 · 360 μg/d menaquinone-7 group · Adults aged 18 years or older with long-term hemodialysis | 360 mcg | 6 weeks | — |
| PIVKA-II plasma levels as markers of subclinical vitamin K deficiency in term infants 2012 · G I (25 μg/die vitamin K) · Term, exclusively breast-fed newborns | 25 mcg | 60 days | — |
| PIVKA-II plasma levels as markers of subclinical vitamin K deficiency in term infants 2012 · G II (12 μg/die vitamin K) · Term, exclusively breast-fed newborns | 12 mcg | 60 days | — |
| Effects of Vitamin K on Matrix Metalloproteinase-3 and Rheumatoid Factor in Women with Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · Vitamin K1 group · Women with rheumatoid arthritis | 10 mg | 8 weeks | — |
| Glycemic control improvement in individuals with type 2 diabetes with vitamin K(2) supplementation: a randomized controlled trial 2021 · vitamin K 2 group · insulin-independent people with type 2 diabetes mellitus | 360 mcg | 12 weeks | — |
| The effect of vitamin K1 on arterial calcification activity in subjects with diabetes mellitus: a post hoc analysis of a double-blind, randomized, placebo-controlled trial 2022 · vitamin K1 supplementation · Individuals with diabetes mellitus and established coronary calcification (coronary calcium score > 10), without clinical coronary artery disease | 10 mg | 90 days | — |
| The Contribution of Lipids to the Interindividual Response of Vitamin K Biomarkers to Vitamin K Supplementation 2019 · treatment group · Men and women aged 60–80 years, generally in good health and free of known coronary disease or osteoporosis | 500 mcg | 3 years | 229 |
| Effect of vitamin K2 treatment on carboxylation of osteocalcin in early postmenopausal women 2006 · vitamin K2 plus vitamin D3 · Postmenopausal women, mean age 53, with osteopenia or osteoporosis and BMD below 0.809 g/cm2 | 45 mg | 2 years | 17 |
| Vitamin D(3) and vitamin K(1) supplementation of Dutch postmenopausal women with normal and low bone mineral densities: effects on serum 25-hydroxyvitamin D and carboxylated osteocalcin 2000 · vitamins K(1)+D(3) · Postmenopausal women about 60 years old with normal or low bone mineral density | 80 mcg | 1 year | — |
| Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women 2007 · 200 microg phylloquinone/d · Postmenopausal women | 200 mcg | 6 weeks | — |
| Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women 2007 · 500 microg phylloquinone/d · Postmenopausal women | 500 mcg | 6 weeks | — |
| Placental transfer of vitamin K1 in preterm pregnancy 1990 · Vitamin K1 treatment group · Women before 35 weeks’ gestation with premature rupture of membranes and/or preterm labor | 20 mg | — | — |
| Vitamin K supplementation and progression of coronary artery calcium in older men and women 2009 · treatment · Healthy older men and postmenopausal women | 500 mcg | 3 years | 200 |
| Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease 2014 · 1000 μg vitamin K/d plus calcium and vitamin D3 group (main RCT) · Adults with Crohn's disease, currently in remission | 1 mg | 1 year | 43 |
| Supplementation with Octacosanol Affects the Level of PCSK9 and Restore Its Physiologic Relation with LDL-C in Patients on Chronic Statin Therapy 2021 · dietary supplement group · Adults aged 40–80 years with hypercholesterolemia or mixed dyslipidaemia, taking atorvastatin chronically | 45 mcg | 13 weeks | 42 |
| Assessment of vitamin A, vitamin B(2), vitamin B(12), vitamin K, folate, and choline status following 4 months of multinutrient supplementation in healthy vegans: a randomised, double-blind, placebo-controlled trial 2025 · INT (intervention group; standard and double omega-3 dosage subgroups) · Healthy adults aged 18 years or older who had followed a vegan diet for at least 1 year; no diagnosed vitamin or mineral deficiency | 50 mcg | 120 days | 35 |
| The effects of vitamin D, K and calcium co-supplementation on carotid intima-media thickness and metabolic status in overweight type 2 diabetic patients with CHD 2016 · vitamin D, vitamin K and calcium supplements · Overweight patients with type 2 diabetes and CHD; age and sex not specified | 180 mcg | 12 weeks | 33 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/HK · Postmenopausal women aged 50–65 years | 23.1 mcg | 12 weeks | 31 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · HD/LK · Postmenopausal women aged 50–65 years | 1.37 mcg | 12 weeks | 31 |
| The Effects of Vitamin D-K-Calcium Co-Supplementation on Endocrine, Inflammation, and Oxidative Stress Biomarkers in Vitamin D-Deficient Women with Polycystic Ovary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial 2016 · vitamin D-K-calcium co-supplementation group · Vitamin D-deficient women aged 18–40 years with polycystic ovary syndrome | 180 mcg | 8 weeks | 30 |
| Reduced bone resorption by intake of dietary vitamin D and K from tailor-made Atlantic salmon: A randomized intervention trial 2016 · LD/HK · Postmenopausal women aged 50–65 years | 23.1 mcg | 12 weeks | 30 |
| The Effects of Calcium, Vitamins D and K co-Supplementation on Markers of Insulin Metabolism and Lipid Profiles in Vitamin D-Deficient Women with Polycystic Ovary Syndrome 2017 · calcium, vitamin D and vitamin K group · Women aged 18–40 years with vitamin D deficiency and polycystic ovary syndrome | 180 mcg | 8 weeks | 28 |
| Vitamin K(2) (menaquinone 4) reduces serum undercarboxylated osteocalcin level as early as 2 weeks in elderly women with established osteoporosis 2003 · MK(4) group · Elderly women with established osteoporosis and vertebral fractures | 45 mg | 2 weeks | — |
| Effect of calcium, vitamins K1 and D3 on bone in galactosemia 2006 · calcium, vitamins K1 and D3 supplementation · Children aged 3–17 years with classical galactosemia | 1 mg | 2 years | — |
| Effect of calcium fortified milk supplementation with or without vitamin K on biochemical markers of bone turnover in premenopausal women 2006 · High calcium skim milk with added phylloquinone · Premenopausal women aged 20 to 35 years | 80 mcg | 16 weeks | — |
| Effect of vitamin K supplementation on insulin resistance in older men and women 2008 · Vitamin K–treated group · Men and postmenopausal women aged 60–80 without diabetes | 500 mcg | 3 years | — |
| Vitamin K2 (menaquinone-7) increases plasma adiponectin but does not affect insulin sensitivity in postmenopausal women: a randomized controlled trial 2021 · MK-7 group · Postmenopausal women; the abstract describes them as healthy | 375 mcg | 1 year | — |
| Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial 2022 · MK-7 plus vitamin D · Elderly men with an aortic valve calcification score >300 AU | 720 mcg | 2 years | — |
| Effects of vitamin K2 and D3 supplementation on epicardial adipose tissue and systemic inflammation: A substudy of the AVADEC trial 2025 · vitamin K2 and D3 group · Men aged 65–74 at cardiovascular risk | 720 mcg | 2 years | — |
| Randomised Controlled Trial of Nutritional Supplement on Bone Turnover Markers in Indian Premenopausal Women 2021 · test group · Premenopausal Indian women aged 25–45 years in good general health, with BMI 18–30 kg/m² | 55 mcg | 180 days | 57 |
| Nutritional supplementation of hop rho iso-alpha acids, berberine, vitamin D₃, and vitamin K₁ produces a favorable bone biomarker profile supporting healthy bone metabolism in postmenopausal women with metabolic syndrome 2011 · intervention arm · Postmenopausal women with metabolic syndrome | 1 mg | 14 weeks | 25 |
| Hop rho iso-alpha acids, berberine, vitamin D3 and vitamin K1 favorably impact biomarkers of bone turnover in postmenopausal women in a 14-week trial 2010 · treatment arm · Healthy postmenopausal women | 1 mg | 14 weeks | 16 |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Caloric restriction-only group (CR) · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 80 mcg | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Moderate-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 80 mcg | 20 weeks | — |
| Osteocalcin carboxylation is not associated with body weight or percent fat changes during weight loss in post-menopausal women 2015 · Vigorous-intensity exercise group · Sedentary post-menopausal women aged 50–70 years with overweight or obesity (BMI 25–40 kg/m²) | 80 mcg | 20 weeks | — |